When Philippe Goix was President of Prism Health Dx (PHDX), they entered into an LOI to do a merger with Avant in Nov, 2016. The deal never went through for some reason. In June 2017, Goix left PHDX and went to Avant to become President there. Then he left Avant in Dec, 2017. A few weeks later, Avant agreed to give back the Dx assets to Amarantus.

So PHDX had obviously done a lot of due diligence on the Dx assets and tried to acquire them through the merger with Avant. PHDX is a private company, so it would have also been a way for them to go public without doing an IPO.

In the pr last week regarding Lympro, it states: " However, prospective collaborators noted that what was missing from our initial dataset was the use of a reference standard that incorporated newly available biomarkers, such as PET imaging."

So maybe one of these prospective collaborators was PHDX? I think its definitely possible that PHDX might still be interested in the Dx assets. Amarantus getting the option for the data might be for a prospective partner, whether its PHDX or someone else. As I've said before, i still think there is a partnership/licensing agreement in the works with one of the assets and I think that Lympro is one of the most likely to license.